Myqorzo is an allosteric inhibitor of cardiac myosin, reducing hypercontractility in obstructive hypertrophic cardiomyopathy, improving heart function. The Phase 3 SEQUOIA-HCM trial showed significant ...
AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed this ...
Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. The ...
Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL). The US regulator ...
Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community practices, addressing regulatory and reimbursement challenges. Education and ...
A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback